KineMarkers™ Overview
 Kinetic Biomarkers - KineMarkers™
1) Give small amount of stable isotope (usually 2H2O ).
2) Label distributes rapidly; new biomolecules are labeled.
3) Cell or biomolecule of interest is isolated from sample.
4) Synthesis or turnover rates determined through ultra-sensitive MS.
Simplistic example:
% new (labeled)/time=synthesis rate
KineMarkers™ by Disease Areas
| Therapeutic Area
|
KineMarker assay — (Indication)
|
Preclinical
|
Clinical
|
| Metabolism
|
Insulin Resistance (Metabolic Syndrome; DM) |
• |
• |
| Pancreatic ß-cell regeneration (diabetes) |
• |
NA |
| Reverse cholesterol transport (C-VD)
|
• |
• |
| Mitochondrial stimulants (obesity)
|
• |
• |
| Neurobiology |
Remyelination stimulators (MS)
|
• |
NA |
| Neurogenesis (depression, injury)
|
• |
NA |
| Neuro-inflammation (AD)
|
• |
NA |
| Microtubule dynamics
|
• |
• |
| Synaptic plasticity (memory, learning)
|
• |
NA |
| Inflammation
|
Anti-fibrogenic agents (lung, liver)
|
• |
• |
| Skin-cell turnover (Psoriasis, Eczema)
|
• |
• |
| Joint space cell/tissue turnover (Arthritis)
|
• |
• |
| Oncology
|
Anti-angiogenic agents
|
• |
• |
| Tumor cell proliferation
|
• |
• |
| Hypomethylation/RR inhibition
|
• |
• |
| Urology
|
Prostate cell proliferation (BPH)
|
• |
• |
|
Back To Top
|
